|
TGFBR2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.9611199999936E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.227000E-04 |
| Normal-vs-Stage2 |
2.389200E-01 |
| Normal-vs-Stage3 |
7.82119999986897E-07 |
| Normal-vs-Stage4 |
1.74869996261151E-09 |
| Stage1-vs-Stage2 |
2.337600E-01 |
| Stage1-vs-Stage3 |
8.116800E-03 |
| Stage1-vs-Stage4 |
2.43059999999184E-05 |
| Stage2-vs-Stage3 |
1.050000E-02 |
| Stage2-vs-Stage4 |
4.568600E-04 |
| Stage3-vs-Stage4 |
1.142150E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.47969999999498E-05 |
| Normal-vs-AfricanAmerican |
1.317850E-03 |
| Normal-vs-Asian |
3.595200E-03 |
| Caucasian-vs-AfricanAmerican |
6.872200E-01 |
| Caucasian-vs-Asian |
8.215600E-01 |
| AfricanAmerican-vs-Asian |
6.176800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.423600E-04 |
| Normal-vs-Female |
2.3369999999967E-05 |
| Male-vs-Female |
9.964000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.777900E-03 |
| Normal-vs-Age(41-60Yrs) |
2.40619999999359E-05 |
| Normal-vs-Age(61-80Yrs) |
9.7943999999961E-05 |
| Normal-vs-Age(81-100Yrs) |
3.427500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.606200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.183800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.989200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.517400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.692400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.671200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.40669999999055E-05 |
| Classical-VS-Follicular |
1.169570E-01 |
| Classical-VS-Other |
1.269210E-01 |
| Classical-VS-Normal |
2.593200E-04 |
| Tall-VS-Follicular |
1.5986400000001E-05 |
| Tall-VS-Other |
9.413800E-01 |
| Tall-VS-Normal |
5.46810041690549E-10 |
| Follicular-VS-Other |
9.657700E-02 |
| Follicular-VS-Normal |
8.836500E-02 |
| Other-VS-Normal |
1.339690E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.320650E-03 |
| Normal-vs-N1 |
2.76830000034423E-07 |
| N0-vs-N1 |
3.923600E-03 |
|
|
